Literature DB >> 9686375

Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G-->A point mutation.

A B van Kuilenburg1, P Vreken, L V Beex, R A De Abreu, A H van Gennip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9686375     DOI： 10.1023/a:1005384609289

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  16 in total

1.  Subcellular localization of dihydropyrimidine dehydrogenase.

Authors:  A B Van Kuilenburg; H Van Lenthe; R J Wanders; A H Van Gennip
Journal:  Biol Chem       Date:  1997-09       Impact factor: 3.915

2.  Pigmentary effects from the protracted infusion of 5-fluorouracil.

Authors:  E Perlin; J D Ahlgren
Journal:  Int J Dermatol       Date:  1991-01       Impact factor: 2.736

Review 3.  Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects.

Authors:  A H van Gennip; N G Abeling; P Vreken; A B van Kuilenburg
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

4.  A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency.

Authors:  P Vreken; A B Van Kuilenburg; R Meinsma; G P Smit; H D Bakker; R A De Abreu; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

5.  Clinical and biochemical findings in six patients with pyrimidine degradation defects.

Authors:  A H van Gennip; N G Abeling; A E Stroomer; H van Lenthe; H D Bakker
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

6.  Clinical cardiotoxicity of 5-fluorouracil.

Authors:  D L Keefe; N Roistacher; M K Pierri
Journal:  J Clin Pharmacol       Date:  1993-11       Impact factor: 3.126

7.  Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.

Authors:  Z Lu; R Zhang; R B Diasio
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

8.  Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes.

Authors:  P Fernandez-Salguero; F J Gonzalez; M C Etienne; G Milano; S Kimura
Journal:  Biochem Pharmacol       Date:  1995-09-28       Impact factor: 5.858

9.  Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea.

Authors:  R Meinsma; P Fernandez-Salguero; A B Van Kuilenburg; A H Van Gennip; F J Gonzalez
Journal:  DNA Cell Biol       Date:  1995-01       Impact factor: 3.311

10.  Identification and tissue-specific expression of a NADH-dependent activity of dihydropyrimidine dehydrogenase in man.

Authors:  A B Van Kuilenburg; H Van Lenthe; A H Van Gennip
Journal:  Anticancer Res       Date:  1996 Jan-Feb       Impact factor: 2.480
View more
  2 in total

Review 1.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

2.  Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

Authors:  Samar Ismail Hamdy; Masahiro Hiratsuka; Kaori Narahara; Mervat El-Enany; Nadia Moursi; Mohammed Salah-Eldin Ahmed; Michinao Mizugaki
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.